Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study

References

• IDF Diabetes Atlas. Reports [cited 2022 Jan 22]. Available from: https://diabetesatlas.org/2022-reports/
   Google Scholar
• Chai S, Zhang R, Zhang Y, et al. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Front Endocrinol. 2022 Aug 9;13:935039. doi: 10.3389/fendo.2022.935039
   PubMed Web of Science ®Google Scholar
• Rabizadeh S, Tavakoli Ardakani MA, Mouodi M, et al. DPP4 inhibitors in the management of hospitalized patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Adv Ther. 2020;37(9):3660–3675. doi: 10.1007/s12325-020-01434-7
   PubMed Web of Science ®Google Scholar
• Singh H, Chakrawarti A, Singh H, et al. Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: a cross-sectional comparative study. J Family Med Prim Care. 2018;7(1):70–76. doi: 10.4103/jfmpc.jfmpc_89_17
   PubMedGoogle Scholar
• Singh H, Singh J, Bhangu RK, et al. Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert Rev Clin Pharmacol. 2023;16(1):49–59.
   PubMed Web of Science ®Google Scholar
• Singh H, Arora E, Narula S, et al. Finding the most cost-effective option from commonly used dipeptidyl peptidase-4 inhibitors in India: a systematic study. Expert Rev Endocrinol Metab. 2023;18(4):347–354.
   PubMed Web of Science ®Google Scholar
• Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254–1264. doi: 10.2522/ptj.20080020
   PubMed Web of Science ®Google Scholar
• Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604–609.
   PubMed Web of Science ®Google Scholar
• Gupta V, Kalra S. Choosing a gliptin. Indian J Endocr Metab. 2011;15(4):298–308. doi: 10.4103/2230-8210.85583
   PubMedGoogle Scholar
• Ramanathan B. DPP-4 inhibitors in the management of type 2 diabetes mellitus. [cited Jan 31, 2022]. Available from: https://apiindia.org/wp-content/uploads/pdf/progress_in_medicine_2017/mu_43.pdf
   Google Scholar
• Adiponectin ELISA. [cited 2023 Jan 31]. Available from: https://dbc-labs.com/wp-content/uploads/pdfs/Adiponectin-ELISA.pdf
   Google Scholar
• DRG® Insulin ELISA (EIA-2935). [cited 2023 Mar 27]. Available from: https://www.sceti.co.jp/images/psearch/pdf/DRG_EIA2935_p.pdf
   Google Scholar
• Patarrãoa RS, Lauttb WW, Macedoc MP. Assessment of methods and indexes of insulin sensitivity. Rev Port Endocrinol Diabetes Metab. 2014;9(1):65‐73. doi: 10.1016/j.rpedm.2013.10.004
   Google Scholar
• Basila AM, Hernández JM, Alarcón ML. Diagnostic methods of insulin resistance in a pediatric population. Bol Med Hosp Infant Mex. 2011;68(5):367‐373.
   Google Scholar
• Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010;1(2):36‐47. doi: 10.4239/wjd.v1.i2.36
   Google Scholar
• Kim HJ, Kim YS, Lee CB, et al. Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: a 12-week interim report. Diabetes Ther. 2019;10(4):1271–1282.
   PubMed Web of Science ®Google Scholar
• Sagara M, Suzuki K, Aoki C, et al. Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study. Cardiovasc Diabetol. 2016;15(1):76.
   PubMedGoogle Scholar
• Tanaka K, Okada Y, Mori H, et al. Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. Diabetol Int. 2016;7(4):368–374.
   PubMedGoogle Scholar
• Jayanthi CR, Subash A, Raveendra KR. Comparison of efficacy and safety of teneligliptin versus sitagliptin as add on to metformin in type 2 diabetes mellitus at a tertiary care hospital. Int J Res Pharmacol Pharmacother. 2017;6(2):208–217.
   Google Scholar
• Chudiwal TB. Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity. Int J Basic Clin Pharmacol. 2017;6(7):1682–1688. doi: 10.18203/2319-2003.ijbcp20172731
   Google Scholar
• Mohan V, Ramu M, Poongothai S, et al. A prospective, open-label, randomized study comparing efficacy and safety of teneligliptin versus sitagliptin in Indian patients with inadequately controlled type 2 diabetes mellitus: INSITES study. J Assoc Physicians India. 2019 Oct;67(10):14–19.
   PubMedGoogle Scholar
• Panikar V, Joshi S, Tiwaskar M, et al. Efficacy of DPP4i as the fourth drug in the management of type2 diabetes mellitus in Asian Indians poorly controlled by use of at least 3 oral antidiabetic drugs. J Assoc Physicians India. 2019 Aug;67(8):60–62.
   PubMedGoogle Scholar
• Li X, Huang X, Bai C, et al. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2018;9:449. doi: 10.3389/fphar.2018.00449
   PubMed Web of Science ®Google Scholar
• Ji L, Ma J, Lu W, et al. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. J Diabetes Investig. 2021;12(4):537–545.
   PubMed Web of Science ®Google Scholar
• Ji L, Li L, Ma J, et al. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: a phase 3, randomized, double-blind, placebo-controlled study. Endocrinol Diabetes Metab. 2021;4(2):e00222.
   PubMedGoogle Scholar
• Tsuchimochi W, Ueno H, Yamashita E, et al. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J. 2015;62(1):13–20. Epub 2014 Sep 25. PMID: 25252844. doi: 10.1507/endocrj.EJ14-0393
   PubMed Web of Science ®Google Scholar
• Yajima T, Yajima K, Hayashi M, et al. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. Diabet Res Clin Pract. 2016 Dec;122:78–83
   PubMed Web of Science ®Google Scholar
• Fujita H, Fujishima H, Koshimura J, et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J. 2005;52(4):427–433. doi: 10.1507/endocrj.52.427
   PubMed Web of Science ®Google Scholar
• Liu X, Men P, Wang Y, et al. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15(1):204. doi: 10.1186/s12944-016-0372-7
   PubMedGoogle Scholar
• Hashikata T, Yamaoka-Tojo M, Kakizaki R, et al. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels. 2016 Aug;31(8):1303–10. Epub 2015 Aug 13. Erratum in: Heart Vessels. 2016 (8):1311-2. doi: 10.1007/s00380-015-0724-7.
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89(6):2563–2568. doi: 10.1210/jc.2004-0518
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel PJ, Utzschneider K, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459–469.
   PubMed Web of Science ®Google Scholar
• Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care. 2003;26(7):2015–2020.
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Li Q, et al. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diab Obes Metab. 2008;10(10):921–930.
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Kondo T, Goto R, et al. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovasc Diabetol. 2013;12(1):160.
   PubMedGoogle Scholar
• Sakr HF. Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J Physiol Pharmacol. 2013;64(5):613–623.
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabet Res Clin Pract. 2012;98(1):51–60.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2010;59(6):887–895.
   PubMed Web of Science ®Google Scholar
• Hibuse T, Maeda N, Kishida K, et al. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus – a randomized controlled trial STARTJ study. Cardiovasc Diabetol. 2014;13(1):96.
   PubMedGoogle Scholar
• Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–1370.
   PubMed Web of Science ®Google Scholar
• Forst T, Dworak M, Berndt-Zipfel C, et al. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus. Diab Obes Metab. 2013;15(6):576–579.
   PubMed Web of Science ®Google Scholar
• Shestakova MV, Suhareva OI, Chernova TO, et al. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition]. Ter Arkh. 2013;85(8):49–55.
   PubMed Web of Science ®Google Scholar
• Liu X, Men P, Wang Y, et al. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15(1):1–9.
   PubMedGoogle Scholar
• Omoto S, Taniura T, Nishizawa T, et al. Antiatherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2015;8:339–345. doi: 10.2147/DMSO.S84545
   PubMed Web of Science ®Google Scholar
• Bae JC, Kwak SH, Kim HJ, et al. Effects of teneligliptin on HbA1c levels, continuous glucose monitoring-derived time in range and glycemic variability in elderly patients with T2DM (TEDDY study). Diabetes Metab J. 2022;46(1):81–92. doi: 10.4093/dmj.2021.0016
   PubMed Web of Science ®Google Scholar
• Saboo B, Erande S, Unnikrishnan AG. A prospective multicentre open label study to assess effect of teneligliptin on glycemic control through parameters of time in range (TIR) metric using continuous glucose monitoring (TOP-TIR study). Diabetes Metab Syndr. 2022;16(2):102394. doi: 10.1016/j.dsx.2022.102394.
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637.
   PubMed Web of Science ®Google Scholar
• Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabet Res Clin Pract. 2008;79(2):291–298.
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571. doi: 10.1007/s00125-006-0416-z
   PubMed Web of Science ®Google Scholar
• Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–180. doi: 10.1111/j.1742-1241.2006.01246.x
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab Obes Metab. 2007;9(5):733–745.
   PubMed Web of Science ®Google Scholar
• Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diab Obes Metab. 2015;17(3):309–312.
   PubMed Web of Science ®Google Scholar
• Agrawal P, Gautam A, Pursnani N, et al. Teneligliptin: an economic and effective DPP-4 inhibitor for the management of type-2 diabetes mellitus: a comparative study. J Assoc Physicians India. 2018;66(8): 67–69. PMID: 31324088.
   PubMedGoogle Scholar
• ORG-IMS Jun 2016. [Accessedcited Jul 27, 2023]. Available from: https://www.imshealth.com/en/about-us/news/top-line-market-data.
   Google Scholar
• Ghosh S, Trivedi S, Sanyal D, et al. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes. 2016;9:347–353. doi: 10.2147/DMSO.S121770
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Chadha M, Ghosh S, et al. Indian expert review on use of teneligliptin in patients with diabetes and its safety and efficacy (INTENSE). J Assoc Physicians India. 2021;69(1):61–70.
   PubMedGoogle Scholar
• National List of Essential Medicines (NLEM), 2022. [cited Aug 15, 2023]. Available from: https://main.mohfw.gov.in/newshighlights-104
   Google Scholar